Loading…
← CockpitCompetitor Analysis › 000989.SZ Jiuzhitang Co., Ltd. Class AOpen in the cockpit ↗

Jiuzhitang Co., Ltd. Class A000989.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Hunan traditional Chinese medicine maker known for classic patent remedies like Liuwei Dihuang Wan sold nationwide.

≈ A Chinese heritage-TCM Nature's BountyMomentum strong 73
Mkt cap
$1.16B
US dollars, full cap
Free float
76%
of shares outstanding
$/day
$15.3M
20-day average traded
Fwd P/E
22.1×
forward earnings
ROIC−WACC
+7.3 pp
WACC 5.9%
Hurdle
+5 pp
Req g minus delivered
Next earnings
128 days
26 Mar 2027
Close · CNYCN¥8.18
1D-1.2%
1W-2.5%
1M-6.9%
3M-14.2%
6M-6.9%
YTD-6.3%
1Y-19.3%
ATR %2.4%
52w lowhigh24.5% off high

What Jiuzhitang does

Hunan traditional Chinese medicine maker known for classic patent remedies like Liuwei Dihuang Wan sold nationwide.

In one line: A Chinese heritage-TCM Nature's Bounty.

Products and services

  • Liuwei Dihuang Wan and other TCM pills
  • Donkey-hide gelatin products
  • Other OTC health products

Customers

  • Retail pharmacies
  • Hospitals

Where it sits in the supply chain

  • Pharmaceuticals
  • Traditional Chinese medicine
  • OTC patent remedies

What could go right

  • Aging population TCM tonic demand

What could go wrong

  • OTC price competition
  • Raw-material cost swings

Moat: narrow (brand). Centuries-old heritage TCM brand name recognized across Chinese pharmacy retail.

Headquarters: Changsha, Hunan, China · Employees: 3,674

Named competitors

Jiuzhitang at a glance

Size Jiuzhitang (000989.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.16B, the 1895th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥8.18 on 18 Nov 2026.

Performance Over six months the shares fell 6.9%, against -11.8% for the median peer and -20.0% for the China market (cap-weighted) — 7th highest of 20 in its peer set.

Growth Revenue grew 45.9% over the last twelve months (peer median -0.9%); the operating margin is 19.2% (peer median 0.8%).

Valuation It trades at 22.1× forward earnings against a peer median of 21.3× (6th most expensive of 12).

Price implies For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is -9%, so the hurdle is +5 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 7.3 points above its cost of capital (5.9% WACC).

Next results Next results expected around 26 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026000989.SZ 95Peer median 86
Six months, rebased to 100: Jiuzhitang against the median of its 20 peers (local-currency closes).

Jiuzhitang financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥2.79BCN¥2.21BCN¥2.35BCN¥2.94BCN¥3.01B
Revenue growth—-6%-20%-2%—
Gross profitCN¥1.72BCN¥1.25BCN¥1.31BCN¥1.70BCN¥1.67B
EBITDAn/aCN¥374MCN¥294MCN¥409MCN¥394M
Net incomeCN¥375MCN¥223MCN¥216MCN¥297MCN¥358M
Free cash flowCN¥644MCN¥398MCN¥137MCN¥48.6MCN¥441M
Capital expenditureCN¥75.9MCN¥40.0MCN¥72.2MCN¥72.8MCN¥96.8M
Total debtCN¥52.3MCN¥136MCN¥134MCN¥186MCN¥127M

Quarterly statements and history in the cockpit →

Jiuzhitang competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%+20%6855NKTR6884436883214547002550688062CMHC3000062616HROW006280VIYASH237690347850IDIAVETO000989.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Jiuzhitang is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%+100%0×200×400×6883214547002550CMHCHROWVIYASH237690300026000989.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Jiuzhitang is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%002550300006VIYASH237690300119300026VETO000989.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Jiuzhitang is the large dot.

Jiuzhitang competitors and peer comparison

Head to head with its named competitors (000989.SZ vs 000423.SZ vs 000999.SZ vs 000538.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Jiuzhitang 000989.SZ$1.16B-7%+46%19%22.1×-4.0%
Dong-E-E-Jiao 000423.SZ$4.99B+1%+8%29%17.8×-3.7%
China Resources Sanjiu Medical & Pharmaceutical 000999.SZ$6.59B+6%+4%14%13.2×-6.2%
Yunnan Baiyao 000538.SZ$15.0B+11%+5%11%18.3×-0.2%

How Jiuzhitang compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Jiuzhitang against its 20 peers (data as of 18 Nov 2026)
Measure000989.SZPeer medianRank in peer set
1-month return-6.9%-1.6%8th lowest of 21
6-month return-6.9%-11.8%7th highest of 20
Distance from 52-week high-24.5%-39.3%5th highest of 21
Revenue growth (TTM)+45.9%-0.9%5th highest of 20
Operating margin19.2%0.8%highest of 20
Forward P/E22.1×21.3×6th most expensive of 12
Growth the price implies (Req g, 7 yrs)-4.0%4.9%least demanding of 8
Growth delivered (Del g)-9.0%+4.2%2nd lowest of 8
Hurdle (Req g minus delivered)+4.9 pp+4.6 pp4th most demanding of 8
ROIC minus cost of capital+7.3 pp-5.6 pp2nd highest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Jiuzhitang 000989.SZChina$1.16B-7%+46%19%22.1×-4.0%-9.0%
Ascentage Pharma Group International 6855.HKHong Kong$1.18B-34%+70%-220%n/an/an/a
Nektar Therapeutics NKTRUnited States$1.18B-50%-17%-304%n/an/an/a
Chongqing Genrix Biopharmaceutical 688443.SSChina$1.18B-22%+256%-27%n/an/an/a
Shenzhen Chipscreen Biosciences 688321.SSChina$1.18B-38%+27%12%60.4×n/an/a
Kissei Pharmaceutical 4547.TJapan$1.14B+3%+6%6%14.5×n/an/a
Changzhou Qianhong Bio-Pharma 002550.SZChina$1.14B-12%-2%15%18.4×3.4%-1.2%
Mabwell (Shanghai) Bioscience 688062.SSChina$1.20B-46%+15%-129%n/an/an/a
Cosmo CMHC.SWSwitzerland$1.13B-30%-45%-13%418.7×n/an/a
Chongqing Lummy Pharmaceutical 300006.SZChina$1.21B+26%-6%-19%n/a44.1%-13.2%
CStone Pharmaceuticals 2616.HKHong Kong$1.21B-22%+117%-89%n/an/an/a
Harrow HROWUnited States$1.21B+4%+21%1%26.8×n/an/a
GC Biopharma 006280.KSSouth Korea$1.12B-10%-3%4%4.6×n/an/a
Symbiotec Pharmalab SYMBIOTEC.NSIndia$1.12Bn/an/an/an/an/an/a
Viyash Scientific VIYASH.NSIndia$1.11B+3%+124%13%32.2×36.3%+20.4%
ST Pharm 237690.KSSouth Korea$1.11B-51%+26%18%27.8×4.2%+21.7%
D&D Pharmatech 347850.KSSouth Korea$1.22B-49%-77%-2,324%n/an/an/a
Tianjin Ringpu Bio-technology 300119.SZChina$1.11B-7%-9%11%18.1×4.9%+11.3%
Idorsia IDIA.SWSwitzerland$1.22B-9%-5%-70%n/an/an/a
Tianjin Chase Sun Pharmaceutical 300026.SZChina$1.23B-10%-29%3%21.3×7.0%-5.3%
Vetoquinol VETO.PAFrance$1.10B+19%-1%15%15.5×-3.6%+4.2%

Questions

Who are Jiuzhitang's main competitors?
Named competitors: Dong-E-E-Jiao (000423.SZ), China Resources Sanjiu (000999.SZ), Yunnan Baiyao (000538.SZ). The cockpit's measured peer set (industry) also includes Ascentage Pharma Group International (6855.HK), Nektar Therapeutics (NKTR), Chongqing Genrix Biopharmaceutical (688443.SS), Shenzhen Chipscreen Biosciences (688321.SS), Kissei Pharmaceutical (4547.T), Changzhou Qianhong Bio-Pharma (002550.SZ).
Is Jiuzhitang expensive compared with its peers?
On forward p/e it trades at 22.1× against a peer median of 21.3×, 6th most expensive of 12 in its peer set. For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is -9%, so the hurdle is +5 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Jiuzhitang stock performed?
Over six months to 18 Nov 2026 the shares returned -6.9% against -11.8% for the median peer; over one year -19.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.